Topic: neurological disorders
Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.
Seer emerged from stealth with $36 million to develop early-warning blood tests for cancer and neurological diseases that query the body’s proteome.
The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance.
Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.
Neurimmune's antibody targets the misfolded SOD1 protein that has been implicated in a subset of ALS cases.
Roche and Icagen have inked a licensing and collaboration deal around ion channel modulators for neurological disorders.
Domain Therapeutics has another big pharma partner, signing a deal with Boehringer Ingelheim to develop new drugs for CNS disorders.
After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Two years after its founding, Biomatics Capital Partners has raised $300 million for its second fund and signed on two new venture partners.